Genomics Medicine Ireland (GMI) was founded in 2015 with the objective of solving diseases of genetic origin by creating large-scale, population-based medical research studies on the island of Ireland to examine the relationship between genetics, health and disease.
After the discovery that computing chips modelled after neurons can process information faster than the human brain, there is new potential for more natural machine-learning software.
Researchers have discovered genome-wide DNA methylation signatures for a number of neurodevelopmental Mendelian disorders, which could prove useful when testing for several syndromes at once, as well helping to classify variants of unknown significance.
We attended ‘The Great Genome Sequencing Debate’ earlier this week, chaired by Vivienne Parry from Genomics England, to discuss the future of genomic testing.
Congenica has announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. He has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses.
A team of researchers have sequenced the genome of the axolotl, and with its ability to regenerate limbs and organs, they are optimistic about what this will mean for the future of medical practices.
After receiving $60 million in its series D funding round, Eureka Therapuetics is able to kick start its phase 1 trial for its lead candidate, a T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma.
Paul focuses on the possibilities for big data in biomedicine, using computationally intensive approaches, including deep learning and graph databases.
SOPHiA GENETICS announced at the Precision Medicine World Conference (PMWC) in Silicon Valley that its artificial intelligence, SOPHiA, has gained radiomics capabilities.
Although very much disagreeing with biohacking practices, and strongly discouraging them, the FDA has never actually intervened themselves with individuals. Should they?
A huge step towards one of the biggest goals in medicine has been taken, with the development of a universal blood test for cancer.
We bring genomics to the UK in our latest issue, as we look ahead to what this year’s Festival of Genomics London has to offer.
As the promise of liquid biopsies continues to impress, startups have already begun selling cheap cancer screening. But, still in its early stages, are they rushing it?
At ASHG, we spoke to Gavin Stone, Vice President of Marketing at Edico Genome, to discuss their World Record achievement in more detail, as well as the advantages offered by their DRAGEN tool.
Two new cancer treatments have shown miraculous cures, but if you happen to live in a handful of rural states in the U.S. (let alone outside the U.S.) — you’ll have to travel hundreds of miles to get them. And it’s by no means certain that they’ll eventually be available everywhere.